PPARδ Induces Estrogen Receptor-Positive Mammary Neoplasia through an Inflammatory and Metabolic Phenotype Linked to mTOR Activation

Hongyan Yuan1, Jin Lu1, Junfeng Xiao1, Geeta Upadhayay1, Rachel Umana6, Bhaskar Kallakury2, Yuhzi Yin3, Michael E. Fant5, Levy Kopelovich4, and Robert I. Glazer1

Abstract

The peroxisome proliferator-activated receptor-δ (PPARδ) regulates a multitude of physiological processes associated with glucose and lipid metabolism, inflammation, and proliferation. One or more of these processes are potential risk factors for the ability of PPARδ agonists to promote tumorigenesis in the mammary gland. In this study, we describe a new transgenic mouse model in which activation of PPARδ in the mammary epithelium by endogenous or synthetic ligands resulted in progressive histopathologic changes that culminated in the appearance of estrogen receptor- and progesterone receptor-positive and ErbB2-negative infiltrating ductal carcinomas. Multiparous mice presented with mammary carcinomas after a latency of 12 months, and administration of the PPARδ ligand GW501516 reduced tumor latency to 5 months. Histopathologic changes occurred concurrently with an increase in an inflammatory, invasive, metabolic, and proliferative gene signature, including expression of the trophoblast gene, Plac1, beginning 1 week after GW501516 treatment, and remained elevated throughout tumorigenesis. The appearance of malignant changes correlated with a pronounced increase in phosphatidylcholine and lysophosphatidic acid metabolites, which coincided with activation of Akt and mTOR signaling that were attenuated by treatment with the mTOR inhibitor everolimus. Our findings are the first to show a direct role of PPARδ in the pathogenesis of mammary tumorigenesis, and suggest a rationale for therapeutic approaches to prevent and treat this disease.

Cancer Res; 73(14); 4349–61. ©2013 AACR.

Introduction

The peroxisome proliferator-activated receptors (PPAR) represent a subfamily of ligand-dependent nuclear receptors that regulate the transcription of a multitude of processes associated with metabolism, angiogenesis, inflammation, and proliferation (1, 2). Of the 3 isotypes, PPARβ/δ alone was shown more than a decade ago to stimulate mitotic clonal expansion of progenitor cells (3, 4). It was conceivable, therefore, that the selective PPARδ agonist GW501516 (GW; ref. 5) would act as a tumor promoter in mammary carcinogenesis, which proved to be the case (ref. 6; reviewed in refs. 7 and 8). GW and related agonists enhance adenoma size and angiogenesis in APC<sup>min</sup> mice (9, 10) and stimulate the growth of several lung (11), breast, and prostate cancer cell lines (12, 13), although results to the contrary have also been reported (14). Conversely, disruption of PPARδ expression in colon cancer cells by somatic cell knockout (15) or RNA aptamers (16) inhibited tumor cell growth. These findings are consistent with those showing that homozygous deletion of PPARδ reduces tumorigenesis in MMTV-Cox2 mice (17), intestinal adenomas in APC<sup>min</sup> mice (18), colon carcinogenesis (19), and pancreatic tumor xenograft growth and angiogenesis in stromal tissue (20). Clinically, PPARδ is an important prognostic marker, wherein 50% of invasive breast cancers expressed moderate to high levels of PPARδ protein (7), and 65% of invasive breast cancer expressed elevated levels of PPARδ mRNA whereas the reverse is true for normal breast (https://www.oncomine.org/resource/ TCGA database). That high expression of PPARδ mRNA was associated with poor survival in breast cancer patients regardless of subtype (21) emphasizes the importance of this nuclear receptor in this disease.

Obesity and inflammation are cancer risk factors (22), which ultimately result in the generation of endogenous PPARδ ligands (23). These include arachidonic acid metabolites prostaglandin PGI<sub>2</sub> (24) synthesized via Cox2/Pges2 (25), 15-HETE

---

Authors' Affiliations: 1Department of Oncology and Lombardi Comprehensive Cancer Center, Lombardi Comprehensive Cancer Center; 2Department of Pathology, Georgetown University, Washington, District of Columbia; 3Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health; 4Chemoprevention Agent Development and Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland; 5Department of Pediatrics, University of South Florida, Tampa, Florida; and 6University of Chicago, Chicago, Illinois

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org).

Corresponding Author: Robert I. Glazer, Georgetown University, 3970 Reservoir Road, NW, Washington, DC 20057. Phone: 202-687-8324; Fax: 202-687-7505; E-mail: glazerr@georgetown.edu

doi: 10.1158/0008-5472.CAN-13-0322

©2013 American Association for Cancer Research.
(26), and polyunsaturated fatty acids (27–29). GW increased arachidonic and linoleic acid levels in the mammary gland during carcinogenesis (30), which was associated with activation of PDK1 and Akt (30–32) and reduction of PTEN (11, 33), signaling pathways that facilitate mammary hyperplasia (30, 34, 35). Although, the aforementioned studies implicate PPARδ as a modulator of tumorigenesis, there is no conclusive evidence that PPARδ per se in the mammary gland functions as an unconventional oncogene by inducing tumorigenesis, an invasive, metabolic, and proliferative and inflammatory gene expression signature, a pronounced increase in phospholipid, lysophosphatidic acid (LPA) and phosphatidic acid (PA) biosynthesis, and mTOR pathway activation. These results show that PPARδ functions as an initiator of mammary tumorigenesis, and suggest new therapeutic options for the prevention and treatment of this disease.

Materials and Methods

Materials

GW501516 was synthesized as previously described (36), and was provided by the Chemoprevention Branch, National Cancer Institute, NIH, Bethesda, MD.

Animals

MMTV-PPARδ mice were generated by pronuclear injection of FVB mouse embryos as previously described (37). The mouse PPARδ cDNA (38) was provided by Dr. Paul Grimaldi, INSERM (Faculté de Médecine, Nice, France), and amplified and cloned into the EcoRI site in MMTV-SV40-Bssk provided by Dr. William Muller, McMaster University (Hamilton, Ontario, Canada). All inserts were confirmed by sequencing. The MMTV-PPARδ construct was digested with Sal I–Spc I, purified, and used for microinjection. Positive animals were identified by PCR using 3 primer pairs: (i) PPARδ-forward: TCT TCA TCG CGG CCA TCA TT, and SV40PolyA-reverse: GTC CAA TTA TGT CAC ACC ACA GAA G, which amplifies a 245 bp transgene fragment; (ii) PPARδ-forward: GCA TGA AGC TCG AGT ATG AGA AGT G, PPARδ-reverse: CTT AGA GAA GGC CTF CAG GTC, which amplifies a 1.2 kbp genomic fragment and a 245 bp cDNA fragment; and (iii) PPARδ-forward: CCT TTG TCA TCC ACC ACA TC and MMTV-reverse: TCA GCA GTA GCC TCA TCA TC, which amplifies a 870 bp transgene fragment.

Animals were fed either Purina 5001 Rodent Chow or chow supplemented with 0.005% (w/w) GW (6). Everolimus (provided by Novartis) was administered at doses of 10 and 20 mg/kg/d as a nanoemulsion diluted in water by oral gavage for 14 days beginning 4 weeks after mice were placed on the GW diet. All animal studies were conducted under protocols approved by the Georgetown University Animal Care and Use Committee in accordance with NIH guidelines for the ethical treatment of animals.

Statistical analysis

Statistical analyses were conducted using a 2-sided log-rank test using GraphPad Prism version 4.03. Differences were considered significant at \( P < 0.05 \).

Histopathology, immunohistochemistry, and Western blotting

Mammary tissue and tumors were excised, and formalin-fixed, paraffin-embedded sections were prepared for hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC). Antigen retrieval was carried out by incubation of tissue sections in 10 mmol/L sodium citrate buffer (pH 6.0) for 20 minutes at a subboiling temperature in an electric steamer as previously described (6, 37). Endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 10 minutes, and incubated for 30 minutes with blocking solution (10% goat serum in Tris-buffered saline), followed by incubation overnight at 4°C with the appropriate primary antibody diluted in blocking solution. Biotin-conjugated secondary antibodies were diluted in TBS containing 0.1% Tween-20 and incubated for 30 minutes at room temperature using the ABC Vectastain (Vector Laboratories) detection system and diaminobenzidine (Pierce), and slides were counterstained with Harris-modified hematoxylin (Thermo-Fisher, Inc.). Western blotting was carried out as previously described (6, 30, 37, 39, 40). Antibodies and their dilutions for IHC and Western blotting are listed in Supplementary Table S1.

Gene microarray analysis

Microarray analysis was carried out as previously described (6, 30, 37, 39, 40). Briefly, tissue was excised, washed in PBS, and stored in RNAlater (Ambion) at −20°C until RNA extraction. Tissue was snap-frozen in liquid nitrogen, pulverized in a mortar and pestle, and RNA extracted using an RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. RNA purity was assessed by an \( A_{260}/A_{280} \) ratio of \( \geq 1.9 \), and by the integrity of 18S and 28S rRNA using an Agilent microfluidic chip. Array analysis was carried out on cRNA prepared from equal amounts of RNA (1 µg) pooled from 5 mice per group. Biotin-labeled cRNA was fragmented at 94°C for 35 minutes and hybridized overnight to an Affymetrix mouse 430A 2.0 GeneChip representing approximately 14,000 annotated mouse genes. GeneChip’s were scanned with an Agilent Gene Array scanner, and grid alignment and raw data generation with the Affymetrix GeneChip Operating software 1.1. A noise value (Q) based on the variance of low-intensity probe cells was used to calculate a minimum threshold for each GeneChip. Samples were averaged and data refined by eliminating genes with signal intensities <300 in both comparison groups, and heat maps were generated from \( \geq 3 \)-fold changes in gene expression normalized to control tissue using unsupervised hierarchical cluster analysis as previously described (41). Gene interaction and ontology analysis used Ariadne Pathway Studio version 9.1 (Supplementary Fig. S3). Datasets have been deposited in the GEO public database under accession no. GSE34109.

Quantitative real-time PCR

Total RNA was extracted as described earlier, and equal amounts of RNA (1 µg) were pooled from each group (5 samples per group) and reverse transcribed with the Omniscript RT Kit (Qiagen) in a total volume of 20 µL as
previously described (6, 30, 37, 39, 40). PCR was done in triplicate using an ABI-Prism 7700 (Applied Biosystems) with SYBRGreen I detection (Qiagen) according to the manufacturer’s protocol. Amplification using the appropriate primers (Supplementary Table S2) was confirmed by ethidium bromide staining of the PCR products on an agarose gel. The expression of each target gene was normalized to GAPDH and is presented as the ratio of the target gene to GAPDH expression calculated using the formula, $2^{-\Delta Ct}$, where $\Delta Ct = Ct_{Target} - Ct_{GAPDH}$ (39).

**Metabolomic analysis**

Analysis was done using ultraperformance liquid chromatography (UPLC) electrospray ionization time-of-flight mass spectrometry (42) by the Proteomic and Metabolomic Shared Resource, Lombardi Comprehensive Cancer Center, Georgetown University. Experimental groups consisted of mammary glands from each of 5 control wild-type and transgenic littermates and an equal number maintained on a diet containing 0.005% GW for 11 weeks (6, 30). Tissue was snap-frozen in liquid nitrogen and stored at $-80^\circ C$. Extracts were prepared in 1 mL chilled 50% methanol containing internal standards (debrisoquine, 1 ng/mL and nitrobenzoic acid, 5 ng/mL) using MagNAlyser Green Beads and a MagNA Lyser agitator (Roche). Samples were clarified, and processing and multivariate analysis conducted as described (42). Each sample (5 µL) was injected onto a reverse-phase 50 × 2.1 mm ACQUITY 1.7-µm C18 column (Waters Corp.) using an ACQUITY UPLC system (Waters) with a gradient mobile phase consisting of water containing 0.1% formic acid (A), acetonitrile containing 0.1% formic acid (B), and 90% isopropyl alcohol in acetonitrile containing 0.1% formic acid and 10 mmol/L ammonium formate (C) at a flow rate of 0.5 mL/min. The gradient consisted of 98% A for 1.0 minutes then a ramp to 60% B from 1.0 to 4.0 minutes, followed by a ramp to 100% B from 4.0 to 7.0 minutes, then a ramp to 80% C from 7.0 to 9.0 minutes, and a ramp to 98% A from 9.0 to 12.0 minutes. The column eluant was introduced directly into the mass spectrometer by electrospray. Mass spectrometry was done on a G2 quadrupole time of flight (TOF) Waters, operating in both negative and positive ionization mode with a capillary voltage of 3,000 V in positive mode and 2,500 V in negative mode with a sampling cone voltage of 40 V in both modes. The desolvation gas flow was set to 750 L/h and the temperature was set to 350°C. The cone gas flow was 25 L/h, and the source temperature was 120°C. Accurate mass was maintained by introduction of the lock mass of leucine–enkephalin under a flow rate of 2 µL/min for the positive mode (556.277 [M+H]$^+$ and 3 µL/min for the negative mode (554.261 [M+H]$^-$) at a concentration of 250 ng/µL in 50% aqueous acetonitrile using LockSpray interface. UPLC-QTOF data were acquired in centroid mode under full scanning from 50 to 1,200 m/z (mass-to-charge ratio) using MassLynx software (Waters).

**UPLC-QTOF datasets and analysis.** Each sample was run in duplicate in both positive and negative modes and the raw data were converted into Network Common Data Form (NetCDF) using MassLynx software. The XCMS package (43) was used to preprocess each of 3 UPLC-QTOF MS datasets separately. To enable further analysis and visualization of the datasets, all m/z values were binned to fixed m/z values with a bin size of 100 ppm. As a result, the data were transformed into a 2-dimensional matrix of ion abundances. Rows of the matrix represent the ions with specific retention time and (m/z) values, whereas columns represent the individual samples. After detecting ions in individual samples, they were aligned across all samples within the corresponding experiment to allow calculation of retention time deviations and relative ion intensity comparison. The parameter design for XCMS package was optimized for UPLC-QTOF high-resolution LC/MS data according to (44). The ions with fold change $>1.5, P < 0.01$ were selected for further analysis. Total ion chromatograms plot, mirror plot, PCA analysis result were provided by XCMS online, box plot and EIC peaks were also generated and sorted in the order of most significant to the least. To select ions with significant and consistent changes between case and controls, the meta analysis was designed to determine overlapping ions among multiple experiments by taking into consideration the presence of a large number of derivative ions such as isotopes, adducts, and fragments. Specifically, the approach used groups ions on the basis of ion annotation obtained using R-package CAMERA. Each ion in a cluster is represented by its monoisotopic mass. This mass is then used to compare ions across multiple experiments. The resulting ion list provides better coverage and more accurate identification of metabolites than those obtained by the traditional approach in which overlapping ions are selected on the basis of their ion mass and merged with those obtained on the basis of their monoisotopic mass calculated through ion annotation. Putative identifications for the resulting ion list were obtained through a mass-based search against 2 databases: Metlin, and Madison Metabolomics Consortium Database. The mass tolerance in the database search was set to 10 ppm for both positive and negative mode data. The m/z values of annotated isotopes/adducts/neutral-loss fragments peaks were converted to the corresponding neutral monoisotopic masses before searching them against the databases. Identities of some putative metabolite identifications were verified by comparing their MS-MS fragmentation patterns and retention time with those of authentic standard compounds.

**Results**

**PPARδ transgene activation induces mammary tumorigenesis**

Transgenic mice were generated that expressed the murine PPARδ cDNA under the control of the MMTV 3′-LTR (45) as previously described (30, 35, 37). Two founder lines with germline transmission were identified and founder M-23 was used for further studies (Supplementary Fig. S1A–S1D). Transgenic animals exhibited increased ductal branching beginning at 6 weeks of age, which markedly increased after animals were administered a diet supplemented with the PPARδ agonist GW (46) for as little as 1 week (Supplementary Fig. S1E). Maintenance on the GW diet for 6 to 11 weeks resulted in the appearance of abnormal nodules (Supplementary Fig. S1E) that were positive for Ki-67 (Supplementary Fig. 1F). Multiparous female transgenic mice at 12 months of age presented with multifocal moderate to well-differentiated infiltrating
ductal carcinomas, and tumor latency was reduced to 5 months after administration of the GW diet (Fig. 1A and B). To obtain a sense of the stochastic changes associated with tumorigenesis, transgenic and wild-type mice were fed the GW diet for varying intervals (Fig. 1C). Administration of the GW diet for 1 to 6 weeks resulted in a progressive increase in ductal dilatation with inspissated protein and lipid secretions and areas of atypical ductal and lobular dysplasia. By 11 weeks,

**Figure 1.** PPARδ activation promotes mammary neoplasia. A, tumor-free incidence in MMTV-PPARδ mice fed a standard or GW-supplemented diet. Tumor formation differed significantly between untreated or GW501516-treated PPARδ mice (PPARδ+GW) vs. untreated or GW-treated wild-type (WT) mice (WT+GW; P < 0.0001 by the χ² test). GW-treated PPARδ mice (PPARδ+GW) developed tumors more rapidly vs. untreated PPARδ mice (P < 0.0001 by the χ² test). Each time point represents tumor incidence as determined by histological examination postmortem. The number (N) of mice per group at each time point was: WT (N = 8), WT+GW (N = 8), PPARδ (N = 6), and PPARδ+GW (N = 7). B, tumor formation in situ. PPARδ mice fed a standard or GW-supplemented diet presented with multifocal moderate to well-differentiated infiltrating ductal carcinomas at 12 months or 5 months, respectively. Shown are representative mice from each group. H&E, magnification, ×400. C, H&E-stained tissue. GW-treated WT exhibited ductal dilatation and secretory changes after 6 weeks, and increased ductal branching after 11 weeks to 5 months. PPARδ mice presented with increased ductal branching after 6 weeks, lobular dysplasia after 11 weeks, and areas of neoplasia after 5 months. GW-treated PPARδ mice exhibited ductal dilatation with lipid droplets and proteinaceous secretions after 1 week, atypical lobular and ductal hyperplasia after 6 weeks, atypical ductal dysplasia bordering on ductal carcinoma in situ after 11 weeks, and infiltrating ductal carcinomas after 5 months. Magnification, ×400.
lesions appeared that resembled ductal carcinoma *in situ*, and by 5 months animals presented with multifocal infiltrating ductal carcinomas (Fig. 1E). Wild-type animals fed the GW diet exhibited ductal hyperplasia at 11 weeks, but no other histological abnormalities (Fig. 1C; Supplementary Fig. S1E).

Previously we reported that GW increased PPARδ, pPDK1, and pT308Akt expression in the mammary gland of wild-type mice (30). To assess the progressive changes in this signaling pathway, mammary tissue and tumors were analyzed at varying intervals after administration of the GW diet (Fig. 2). Mammary tissue was positive for PPARδ, pT308Akt, pmTOR, and S6 phosphorylation (pS6), as well as the trophoblast protein Plac1, throughout treatment. Tumors were positive for estrogen receptor (ER) and progesterone receptor (PR), and negative for ErbB2, a rare phenotype for genetically engineered breast cancer mouse models (41).

**mTOR activation and everolimus treatment**

Because mTOR signaling paralleled tumorigenesis, animals maintained on the GW diet for 6 weeks were treated during the last 2 weeks on the diet with the mTOR inhibitor everolimus/RAD001 administered by daily gavage at doses of 10 and 20 mg/kg (Fig. 3). Everolimus reverted many of the aberrant premalignant changes in the mammary gland as assessed by whole mounts (Fig. 3A) and H&E staining (Fig. 3B), which correlated with inhibition of pS235/236S6 (Fig. 3C and D) and Ki-67 (Fig. 3D), but not with changes in pT308Akt, pS473Akt, pmTOR, pHEBP, and pAMPKα1 (Fig. 3C). Administration of 20 mg/kg everolimus to mice maintained on the GW diet for 4 months resulted in similar histological changes toward a less malignant phenotype (results not shown).

Gene microarray analysis of everolimus-treated animals revealed several differences between PPARδ-responsive and everolimus-sensitive gene expression (Fig. 3E and F; Supplementary Table S3). Treatment with 10 mg/kg everolimus resulted in changes in 71 genes, of which 70% contained PPAR response elements (PPRE; Supplementary Table S3). Everolimus downregulated expression of PPRE-containing genes associated with differentiation (Krt79, Ltf, and Pvalb), inflammation...
transgenic mice were maintained on the GW diet for 6 weeks and treated with 10 or 20 mg/kg everolimus daily by gavage during the 5th and 6th weeks on the diet. Everolimus reduced lobular hyperplasia and dysplasia induced by GW in transgenic mice. Magnification, ×10. B, H&E stained tissue. Everolimus inhibited pS6, but did not affect the expression of other signaling molecules. D, quantitation of the Western blot in C, E, IHC analysis. Everolimus reduced pS6 and Ki-67 labeling and had a moderate effect on affect Plac1 expression. Magnification, ×400. F, heat map of genes differentially expressed in PPARδ mice maintained on the GW diet for 6 weeks and treated with 10 mg/kg everolimus by gavage daily during the 5th and 6th weeks on the diet (see Supplementary Table S3). G, qRT-PCR analysis of representative genes in F.
changes in the mammary gland elicited by PPARδ activation are mediated by the mTOR-signaling pathway.

**Differential gene expression by PPARδ activation**

To determine the progressive changes induced in gene expression, analyses were carried out with mammary tissue from transgenic and wild-type mice maintained for 1 or 11 weeks on the GW diet (Table 1). Both groups of animals exhibited a common 10 gene PPRE gene signature versus similarly treated wild-type mice, which encompassed inflammation, invasion, proliferation, and metabolism. The gene expression profile of transgenic mice fed the GW diet for 11 weeks is shown in Fig. 4A and B and Supplementary Table S4. Of the 34 genes upregulated in GW-treated PPARδ mice, 70% contained PPREs, including genes associated with differentiation (Anxa8 and Krt14), inflammation (Saa1/2/3, S100A8/9, Il1b, Ccl8, and Ptgs2), invasion (Klk6/7/11 and Mmp12), metabolism, (Acs4 and Crabp1), proliferation (Plac1 and Ccnb1), and transport (Aqp3, Gpr172b, and Slc34a2). In contrast, the gene expression signature of 15-week-old age-matched transgenic mice fed a standard diet included >150 genes, of which 50% contained PPREs (Supplementary Table S5). Approximately

<table>
<thead>
<tr>
<th>Function</th>
<th>Gene Symbol</th>
<th>Raw Score</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GW501516 diet for 1 week</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation</td>
<td>Interleukin 1 family, member 9, Il1f9</td>
<td>18 36 27 356</td>
<td>9.9</td>
</tr>
<tr>
<td></td>
<td>S100 calcium binding protein A8</td>
<td>303 95 238 418</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>Serum amyloid A1, Saa1</td>
<td>15 90 177 3,714</td>
<td>41.3</td>
</tr>
<tr>
<td></td>
<td>Serum amyloid A2, Saa2</td>
<td>6 47 102 2,401</td>
<td>51.1</td>
</tr>
<tr>
<td>Invasion/proliferation</td>
<td>Kallikrein-related peptidase 6, Klk6</td>
<td>72 112 61 1,255</td>
<td>11.2</td>
</tr>
<tr>
<td></td>
<td>Kallikrein-related peptidase 11, Klk11</td>
<td>23 42 53 823</td>
<td>19.6</td>
</tr>
<tr>
<td></td>
<td>Placental-specific 1, Plac1</td>
<td>133 132 136 18,939</td>
<td>143.2</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Acyl-CoA synthetase long-chain family member 4, Acsl4</td>
<td>195 191 183 777</td>
<td>4.1</td>
</tr>
<tr>
<td></td>
<td>Oleoyl-ACP-hydrolase, Olah</td>
<td>4 6 4 1,717</td>
<td>286.2</td>
</tr>
<tr>
<td>Transport</td>
<td>Aquaporin 3, Aqp3</td>
<td>37 29 105 5,688</td>
<td>194.1</td>
</tr>
<tr>
<td><strong>GW501516 diet for 11 weeks</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation</td>
<td>Interleukin 1 family, member 9, Il1f9</td>
<td>58 61 56 629</td>
<td>10.3</td>
</tr>
<tr>
<td></td>
<td>S100 calcium binding protein A8</td>
<td>431 342 415 4,266</td>
<td>12.5</td>
</tr>
<tr>
<td></td>
<td>Serum amyloid A1, Saa1</td>
<td>2,715 1,742 730 14,810</td>
<td>8.5</td>
</tr>
<tr>
<td></td>
<td>Serum amyloid A2, Saa2</td>
<td>1,626 980 409 12,963</td>
<td>13.2</td>
</tr>
<tr>
<td>Invasion/proliferation</td>
<td>Kallikrein-related peptidase 6, Klk6</td>
<td>142 106 101 18,338</td>
<td>173.1</td>
</tr>
<tr>
<td></td>
<td>Kallikrein-related peptidase 1, Klk11</td>
<td>36 70 164 722</td>
<td>10.3</td>
</tr>
<tr>
<td></td>
<td>Placental-specific protei 1, Plac1</td>
<td>31 41 1,497 4,491</td>
<td>108.9</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Acyl-CoA synthetase long-chain family member 4, Acsl4</td>
<td>230 366 372 1,287</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td>Oleoyl-ACP-hydrolase, Olah</td>
<td>21 227 237 1,361</td>
<td>6.0</td>
</tr>
<tr>
<td>Transport</td>
<td>Aquaporin 3, Aqp3</td>
<td>52 114 1,230 4,438</td>
<td>38.9</td>
</tr>
</tbody>
</table>

NOTE: Mice at 4 weeks of age were fed a diet containing 0.005% GW501516 for either 1 or 11 weeks. Shown are ≥3-fold changes in expression in mammary tissue of common PPRE-containing genes with a raw score ≥300 in GW501516-treated MMTV-PPARδ (δ±GW) vs. wild-type littersmates treated with GW501516 (WT±GW).
Figure 4. Gene microarray and metabolomic analyses of GW-treated PPARδ mice. A, shown is a heat map of 34 genes whose expression in mammary tissue was changed >3-fold in PPARδ mice treated with GW for 11 weeks (PPARδ+GW) vs. similarly treated wild-type mice (WT+GW; see Supplementary Table S4). B, qRT-PCR analysis of representative genes presented in A. C, mirror plot of metabolites altered in MMTV-PPARδ mice treated as in A. Depicted are [-] and [+] ions whose intensities between groups were altered >5-fold with a P-value <0.01. Ions that were upregulated are represented as green circles above the plot, and those that were downregulated are represented as red circles below the plot. The size of each circle corresponds to...
Table 2. Metabolites increased in mammary tissue from MMTV-PPARδ mice fed a GW501516 diet

<table>
<thead>
<tr>
<th>molid</th>
<th>rtmed</th>
<th>Fold</th>
<th>P-value</th>
<th>Q-value</th>
<th>Adduct</th>
<th>Mass</th>
<th>dpmm</th>
<th>Name</th>
<th>Link</th>
<th>Mean signal intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>39,543</td>
<td>8.02</td>
<td>612</td>
<td>1.062E-04</td>
<td>4.306E-04</td>
<td>[M+H]+</td>
<td>809.59</td>
<td>0</td>
<td>PC(18:0/20:4)</td>
<td>Metlin</td>
<td>1,253</td>
</tr>
<tr>
<td>75,868</td>
<td>7.94</td>
<td>583</td>
<td>2.312E-04</td>
<td>5.722E-04</td>
<td>[M+H]+</td>
<td>783.58</td>
<td>0</td>
<td>PC(18:0/18:3)</td>
<td>Metlin</td>
<td>1,592</td>
</tr>
<tr>
<td>39,290</td>
<td>8.05</td>
<td>452</td>
<td>2.700E-05</td>
<td>2.436E-04</td>
<td>[M+H]+</td>
<td>767.55</td>
<td>3</td>
<td>PC(15:0/20:4)</td>
<td>Metlin</td>
<td>191</td>
</tr>
<tr>
<td>59,791</td>
<td>8.00</td>
<td>370</td>
<td>4.962E-04</td>
<td>7.861E-04</td>
<td>[M+H]+</td>
<td>833.59</td>
<td>0</td>
<td>PC(20:2/20:4)</td>
<td>Metlin</td>
<td>242</td>
</tr>
<tr>
<td>59,955</td>
<td>7.75</td>
<td>292</td>
<td>2.597E-04</td>
<td>5.980E-04</td>
<td>[M+H]+</td>
<td>827.55</td>
<td>2</td>
<td>PC(20:5/20:4)</td>
<td>Metlin</td>
<td>69</td>
</tr>
<tr>
<td>75,636</td>
<td>7.87</td>
<td>148</td>
<td>2.520E-04</td>
<td>5.875E-04</td>
<td>[M+H]+</td>
<td>739.52</td>
<td>2</td>
<td>PC(13:0/20:4)</td>
<td>Metlin</td>
<td>348</td>
</tr>
<tr>
<td>39,248</td>
<td>7.86</td>
<td>69</td>
<td>6.750E-05</td>
<td>3.607E-04</td>
<td>[M+H]+</td>
<td>753.53</td>
<td>0</td>
<td>PC(14:0/20:4)</td>
<td>Metlin</td>
<td>102</td>
</tr>
<tr>
<td>75,636</td>
<td>7.57</td>
<td>42</td>
<td>2.517E-04</td>
<td>5.875E-04</td>
<td>[M+H]+</td>
<td>739.52</td>
<td>9</td>
<td>PC(13:0/20:4)</td>
<td>Metlin</td>
<td>69</td>
</tr>
<tr>
<td>81,689</td>
<td>7.87</td>
<td>23</td>
<td>2.299E-04</td>
<td>5.71E-04</td>
<td>[M+H]+</td>
<td>786.61</td>
<td>11</td>
<td>PA(20:0/22:1)</td>
<td>Metlin</td>
<td>1,137</td>
</tr>
<tr>
<td>60,185</td>
<td>7.78</td>
<td>17</td>
<td>1.002E-04</td>
<td>4.155E-04</td>
<td>[M+H]+</td>
<td>853.56</td>
<td>0</td>
<td>PC(22:2/20:4)</td>
<td>Metlin</td>
<td>221</td>
</tr>
<tr>
<td>39,290</td>
<td>8.03</td>
<td>636</td>
<td>5.670E-05</td>
<td>1.732E-04</td>
<td>[M+H]+</td>
<td>767.55</td>
<td>1</td>
<td>PC(15:0/20:4)</td>
<td>Metlin</td>
<td>34</td>
</tr>
<tr>
<td>39,290</td>
<td>7.84</td>
<td>411</td>
<td>8.351E-04</td>
<td>8.885E-04</td>
<td>[M+H]+</td>
<td>767.55</td>
<td>0</td>
<td>PC(15:0/20:4)</td>
<td>Metlin</td>
<td>18</td>
</tr>
<tr>
<td>75,853</td>
<td>7.78</td>
<td>277</td>
<td>1.608E-03</td>
<td>1.314E-03</td>
<td>[M+H]+</td>
<td>791.55</td>
<td>3</td>
<td>PC(17:2/20:4)</td>
<td>Metlin</td>
<td>18</td>
</tr>
<tr>
<td>40,903</td>
<td>7.95</td>
<td>275</td>
<td>5.313E-04</td>
<td>6.584E-04</td>
<td>[M+H]+</td>
<td>741.53</td>
<td>0</td>
<td>PA(18:0/20:4)</td>
<td>Metlin</td>
<td>33</td>
</tr>
<tr>
<td>3,406</td>
<td>5.44</td>
<td>244</td>
<td>2.132E-03</td>
<td>1.594E-03</td>
<td>[M+H]+</td>
<td>282.26</td>
<td>1</td>
<td>Oleic acid</td>
<td>Metlin</td>
<td>19</td>
</tr>
<tr>
<td>35,056</td>
<td>5.02</td>
<td>240</td>
<td>1.032E-03</td>
<td>1.002E-03</td>
<td>[M+H]+</td>
<td>304.24</td>
<td>1</td>
<td>Arachidonic acid</td>
<td>Metlin</td>
<td>37</td>
</tr>
<tr>
<td>167</td>
<td>5.33</td>
<td>99</td>
<td>2.263E-03</td>
<td>1.857E-03</td>
<td>[M+H]+</td>
<td>256.24</td>
<td>1</td>
<td>Palmitic acid</td>
<td>Metlin</td>
<td>30</td>
</tr>
<tr>
<td>82,027</td>
<td>7.84</td>
<td>78</td>
<td>1.262E-03</td>
<td>1.100E-03</td>
<td>[M+H]+</td>
<td>752.54</td>
<td>11</td>
<td>PA(20:0/22:4)</td>
<td>Metlin</td>
<td>18</td>
</tr>
<tr>
<td>49,943</td>
<td>5.81</td>
<td>32</td>
<td>1.648E-04</td>
<td>1.328E-03</td>
<td>[M+H]+</td>
<td>438.27</td>
<td>6</td>
<td>LPA(18:0/0:0)</td>
<td>Metlin</td>
<td>23</td>
</tr>
</tbody>
</table>

NOTE: Shown are upregulated metabolites altered in PPARδ mice fed the GW501516 diet for 11 weeks vs. similarly treated wild-type mice (WT−GW). The features included in the table are based on the XCMS algorithms at: http://xcmsonline.scripps.edu (43).

40% of the upregulated genes were associated with mitosis and proliferation, and although consistent with the oncogenic phenotype, were not altered in PPARδ mice treated with GW for 11 weeks. Similarly treated wild-type mice exhibited changes in >130 genes, of which 55% contained PPREs (Supplementary Table S6). Within this profile, only the PPRE-containing motility-associated genes Ttn, Smox, Myot, Myh4, Myh2, Trdn, and Ldb3 were common to the expression profile in untreated transgenic mice, suggesting that most of the changes in gene expression in GW-treated wild-type mice were ancillary to oncogenesis.

Metabolic analysis

To delineate the early metabolic consequences of transgene activation, metabolic analysis was carried out with mammary tissue from wild-type and transgenic mice maintained on the standard or GW-supplemented diets for 11 weeks (Table 2; Fig. 4C; Supplementary Fig. S2). GW-treated PPARδ mice, in
compared to similarly treated wild-type mice, exhibited a marked increase in the levels of phosphatidylcholine (PC) metabolites, arachidonic acid, LPA, and PA. These changes were consistent with the changes in PPARδ-regulated genes, including Plac1 and Ptdgs2 involved in prostaglandin biosynthesis (Supplementary Table S4), and LPA- and PA-mediated activation of mTOR (Fig. 4D).

Discussion

This study describes the first transgenic animal model in which activation of the nuclear receptor PPARδ induces mammary tumorigenesis. Infiltrating adenocarcinomas occurred in all animals within 12 months, and the oncogenic process was rapidly accelerated by activation of the receptor by the agonist GW. In the latter instance, ductal and lobular hyperplasia, dysplasia, and DCIS-like lesions occurred in a stochastic manner over several weeks. Although, the potency of the synthetic ligand likely contributed to the shorter latency of tumor formation, it may also have reflected production of endogenous ligands, including prostaglandins, phospholipids, and unsaturated fatty acids (26, 27, 29, 47) generated downstream of PPARδ activation as noted previously (30, 47) and in this study (Table 2; Fig. 4C). Although, our studies were carried out with one founder line that exhibited high transgene expression, random transgene insertion and activation of another locus may have contributed to the phenotype. However, we consider this possibility unlikely because tumorigenesis was accelerated by the PPARδ ligand GW, which resulted in similar protein and gene expression profiles in unstimulated and stimulated animals. Off-target effects of GW may also have contributed to the observed phenotype, but this would not appreciably affect the interpretation of our data for 2 reasons. First, the dose of GW (6) is equivalent to a daily oral dose of 5 mg/kg that was previously shown to specifically enhance PPARδ-dependent metabolism (48), and its congeners, GW7042, did not alter gene expression in PPARδ knockout mice (49). Second, the gene expression pattern elicited by GW in transgenic mice was unique in comparison to similarly treated wild-type animals.

A signature feature of MMTV-PPARδ mice was the development of ER+/PR+/ErbB2− tumors, characteristics that define the luminal subtype of breast cancer (50). Luminal breast cancer has been further defined by gene expression profiling into subtypes A and B, where type B denotes lower ER expression, higher Ki-67 staining, and a higher histologic grade. By these criteria, tumors arising in PPARδ transgenic mice resemble more the luminal B subtype. Because ER mRNA was relatively low in comparison to immunohistochemical staining, these results also suggest that posttranscriptional regulation of ER may be an important factor in ER expression in PPARδ mice, for example by mTOR-mediated ER phosphorylation (51). In addition, we previously noted increased ER−/PR+/ErbB2− mammary tumors following carcinogenesis in dominant-negative MMTV-Pax6/PPARγ transgenic mice (37) and in wild-type FVB mice treated with the irreversible PPARγ inhibitor GW9662 (52), which supports the concept that PPARγ and PPARδ, either by direct competition (53), cofactor competition (54) and/or ligand-dependent activation and repression (55), have opposing actions that ultimately influence the expansion of the ER+/PR− mammary progenitor lineage. Because other MMTV transgenic mouse models, with the exception of MMTV-AIB1 transgenic mice (56, 57), lack the ER− luminal phenotype (41), this suggests that the PPARδ transgene, rather than the MMTV promoter, drives expansion of the ER− progenitor lineage. This conclusion is further implied by the similarity between MMTV-AIB1 and MMTV-PPARδ mice in activating the Akt/mTOR signaling axis (56, 57), suggesting a scenario where ligand-dependent co-activator recruitment to PPARδ leads to ER− progenitor cell expansion and oncogenesis.

The progressive histopathologic changes resulting from PPARδ activation were associated with upregulation of Plac1, a microvillous membrane protein expressed primarily in trophoblasts and not in other somatic tissues except for low levels in the testes (58). Plac1 expression occurred in transgenic mice, but not to wild-type mice, as early as 1 week after administration of GW (Fig. 1; Table 1), and correlated with the early onset of oncogenesis. Plac1 was reported to be re-expressed in several malignancies (59–61), and reduction of Plac1 in breast cancer cells inhibited proliferation and invasion (59). This suggests that Plac1 may serve as an early marker of oncogenesis or possibly a therapeutic target, as suggested by the more favorable prognosis of colorectal cancer patients expressing Plac1 autoantibodies (62). Analysis of a limited set of paired breast cancer specimens indicated that Plac1 was elevated in all tumor specimens (unpublished results), confirming previous results of changes in Plac1 RNA levels (59, 60). Our data suggest that Plac1 transcription is regulated by PPARδ, but not by mTOR, although everolimus did reduce protein levels. Many of the transcription factors driving transcription of human Plac1 are associated with C/EBPα and C/EBPδ (63), which is consistent with their role as coactivators in complex with PPARδ (64). Although, the human and mouse Plac1 promoter regions were reported to be upregulated by LXR and RXRα (65), neither PPARα agonists nor co-expression with PPARδ were tested, leaving open the question of the direct involvement of PPARδ in the regulation of Plac1 transcription.

PPARδ activation was associated with Akt and mTOR activation as denoted by enhanced pT308Akt and pS6. These results agree with previous studies showing that Akt and pS6 (66–68), but not p4EKB (69), were the best surrogate markers of everolimus activity in experimental tumor models and patients. Everolimus resolved many of the early aberrant histopathologic changes resulting from PPARδ activation that may have resulted from indirect or direct mTOR activation by LPA and PA, respectively (refs. 70 and 71; Table 2; Fig. 4D). This was unexpected in view of the positive effect of PPARδ on fatty acid oxidation in skeletal muscle and fat (72, 73). Gene expression and metabolic profiling, however, suggest that PPARδ upregulates genes essential for promoting a lipogenic phenotype that lead to increased PC, LPA, and PA biosynthesis, which presumably drive activation of the mTOR axis directly (71) and indirectly through G protein–coupled receptors (74). Because long-term testing of everolimus has not been evaluated thus far, we do not know whether mTOR signaling is a major contributor to the malignant changes stemming from PPARδ activation. From a transcriptional standpoint, the mTOR
promoter does not contain PPREs, but the promoter regions of Akt2 and Akt3, but not Akt1, do contain these response elements. Akt can activate mTOR directly (75) and indirectly through activation of Tsc and inhibition of Rheb (76). In addition, the ability of PPARδ to activate Akt is a prerequisite for its growth promoting and antiapoptotic effects (11, 32, 33), including the wound-healing response (77, 78). Thus, modulation of this pathway by PPARδ seems to be a key event in the tumorigenic phenotype exhibited in this mouse model.

Finally, the inflammatory factors Saal, Saa2, S100a8, and S100a9, as well as several members of the kallikrein gene family were selectively increased in GW-treated PPARδ mice (Table 1), and have been reported to be elevated in ERβ breast cancer (79, 80). S100a8 and S100a9 act as ligands for Ager (advanced glycation end-product receptor) and mediate acute and chronic inflammation, tumor development, and metastasis (81, 82), processes previously associated with GW-dependent gastric carcinogenesis (83) and psoriasis (84). This paradigm is consistent with GW-induced activation of Ptg2 and Ptg2/COX-2 expression (85, 86), which initiate the biosynthesis of arachidonic acid and phospholipid metabolites that can serve as PPARδ ligands (Fig. 4D). Because overexpression of Ptg2 in the mammary gland is oncogenic (87), one would expect that PPARδ and inflammation would contribute cooperatively to the development of tumorigenesis in this model.

In summary, we describe a novel ERβ/PR/ErbB2 breast cancer model that is dependent on the activation of PPARδ and its ability to elicit an inflammatory, invasive, metabolic, and proliferative response that culminates in Akt/mTOR activation, which could potentially drive genomic instability (Supplementary Fig. S3). This animal model should prove useful for delineating the role of PPARδ in tumor initiation and progression, and as a possible target for early intervention.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: J. Xiao, L. Kopelovich, R.I. Glazer

Development of methodology: H. Yuan, J. Xiao, G. Upadhyay, Y. Yin, R.I. Glazer

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): H. Yuan, J. Xiao, B.V.S Kallakury, M. Fant, R.I. Glazer

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): H. Yuan, J. Lu, J. Xiao, B.V.S. Kallakury, L. Kopelovich, R.I. Glazer

Writing, review, and/or revision of the manuscript: H. Yuan, J. Lu, B.V.S Kallakury, L. Kopelovich, R.I. Glazer

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): H. Yuan, R. Umans, R.I. Glazer

Study supervision: R.I. Glazer

Grant Support

This work was supported by grant 1R01 CA111482 and contract 1NO1 CN43302-WA19 from the National Cancer Institute, NIH, and award IP30 CA051008 from the National Cancer Institute, NIH to the Lombardi Comprehensive Cancer Center. This investigation was conducted using the Animal Research, Genomics and Epigenomics, and Microscopy and Imaging Shared Resources of the LCCC, and by an animal facilities construction grant from the NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 4, 2013; revised April 18, 2013; accepted April 29, 2013; published OnlineFirst June 27, 2013.

References

Yuan et al.


